Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for ivermectin (topical use), the scientific conclusions are as follows:

Based on the case of acute hepatitis with positive dechallenge reported during the period covered by the PSUSA, the pharmacokinetic properties (significant systemic exposure) of topical ivermectin, the topical use on injured skin and the known risk of increasing ALAT/alkaline phosphatase of *per os* ivermectin, the PRAC considers that the section 4.8 of SmPC should be updated to include the adverse reactions “transaminases increased” with a frequency not known. The package leaflet should be updated accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for ivermectin (topical use) the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing ivermectin (topical use) is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing ivermectin (topical use) are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold,** deleted text ~~**strike through**~~)

Summary of Product Characteristics

- Section 4.8

The following adverse reaction should be added under the SOC Investigations with a frequency not known:

Transaminases increased

Package Leaflet

4. Possible side effects

The following adverse reaction should be added as follows:

[...]

Not known side effect (frequency cannot be estimated from the available data)

- [...]
- **Liver enzyme elevations (ALAT/ASAT)**

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	December 2018 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	26 January 2019
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	27 March 2019